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Abstract
Background: Juvenile idiopathic arthritis (JIA) refers to a number of rare chronic inflammatory diseases. Although
JIA imposes a significant societal burden, limited data are available on the cost of JIA. The study’s objective is to
quantify the socioeconomic burden of JIA patients in the United Kingdom (UK), along with their health-related
quality of life (HRQoL).
Methods: A bottom-up, cross-sectional, cost-of-illness analysis of 23 patients was carried out. To collect data on
demographic characteristics, health resource utilization, informal care, productivity losses and HRQoL, questionnaires
were administered to and completed by patients or their caregivers. The EuroQol five dimensions (EQ-5D)
instrument was used to measure HRQoL.
Results: This study found that the average annual cost for a JIA patient was €31,546, with direct health care costs
equalling €14,509 (46.0 % of total costs), direct non-health care costs amounting to €8,323 (26.4 %) and productivity
losses being €8,715 (27.6 %). This was calculated using unit costs for 2012. The largest expenditures on average
were accounted for by early retirement (27.0 %), followed by informal care (24.1 %), medications (21.1 %),
outpatient and primary health care visits (13.2 %) and diagnostic tests (7.9 %). Important differences existed
between JIA patients in need of caregiver assistance and those with no need (€39,469 vs. €25,452 respectively).
Among adult JIA patients, mean EQ-5D index scores and visual analogue scale (VAS) scores were found to be 0.26
and 49.00 respectively; the same scores among caregivers were 0.66 and 67.14 respectively.
Conclusion: JIA poses a significant cost burden on the UK society. Over half of the total average costs (54 %) are
related to non-health care and productivity losses. HRQoL of JIA patients is considerably worse than the UK general
population.
Keywords: Juvenile idiopathic arthritis, Rare diseases, Cost-of-illness, Socioeconomic cost, Health related quality of
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Background
Juvenile idiopathic arthritis (JIA) refers to a group of dif-
ferent rare disorders, mainly manifesting as chronic in-
flammatory arthritis of unknown etiology. Onset of the
disease occurs before adulthood, progressing to erosive
arthritis and usually causing disability [1]. Subtypes of
JIA include oligoarthritis (40 %), enthesitis-related arth-
ritis (15 %), systemic arthritis (14 %), polyarthritis
(14 %), psoriatic arthritis (1 %), and other arthritis types
(16 %), with all subtypes having different phenotypes,
courses and prognoses [2]. About one in every 1,000
children across the world suffers from JIA [3, 4]. Despite
ethnic differences in prevalence [5] JIA is the type of
chronic rheumatic illness children are most likely to suf-
fer from, causing both short and long-term disability [6].
The international literature reports that children with
JIA live with impaired functions due to joint swelling,
pain and stiffness, with the possibility to experience an
enduring disease activity and disability in adulthood and
throughout their lifespans [7].
Available treatments for JIA patients aim to improve
well-being while minimising side effects; first line treat-
ments for the control of inflammation usually involve
non-steroidal anti-inflammatory drugs and intra-articular
glucocorticoid injections. Second line treatments usually in-
clude disease-modifying anti-rheumatic drugs (DMARDs),
such as methotrexate (MTX) and tumor necrosis factor
(TNF) alpha inhibitors. Predicting patients’ likely response
to MTX can aid the prevention of side effects while
saving time through prompt switch of patients to alter-
native therapies (e.g. biological drugs) in order to pre-
vent irreversible complications [8, 9].
JIA imposes both a significant health burden on pa-
tients’, caregivers’ and families’ lives, as well as an eco-
nomic burden on society due to the substantial health
care costs associated with increased utilization [7, 10–
14] while affecting health-related quality of life
(HRQoL) [15]. Differences are reported among coun-
tries both in the overall magnitude and the main con-
tributor of costs in JIA, whether across sub-types or for
each sub-type. Agreement exists that total mean costs
are highest for active seropositive polyarthritis and low-
est for active enthesitis related arthritis [7, 10–14].
Data on the cost of JIA are less frequently available
than for other illnesses, including lack of a comprehen-
sive study in the United Kingdom (UK). In the present
analysis we present primary JIA data at patient-level
from the UK collected as part of the BURQOL-RD pro-
ject [16]. Our objective is to provide critical insights into
the JIA disease burden, first, by estimating the societal
costs of the disease in terms of direct health care, direct
non-health care and productivity losses, and, second, by
assessing the HRQoL of patients and their caregivers
based on the severity of their disease.
Methods
Research design and sample
The study involved non-institutionalised patients with a
JIA diagnosis receiving outpatient care. A bottom-up,
cross-sectional design was adopted. Patients were re-
cruited from and contacted by the National Rheumatoid
Arthritis Society (NRAS). Patient eligibility criteria in-
cluded a JIA diagnosis, a non-institutionalised status and
a membership with NRAS. Participants were asked to
complete a survey, which was anonymous; none of the
questions contained identification information.
Information and variables of interest
A survey tool was administered to eligible patients by
NRAS electronically and through post in February 2013.
Two main sections comprised the questionnaire, one re-
lating to costs and the other relating to HRQoL. Collec-
tion of data took place between February 2013 and April
2013. Data collected included demographic, clinical and
resource use evidence.
Following data collection, patients were allocated into
two groups for the analysis: a high-severity group that
was in need of caregiver assistance to perform daily
basic (e.g. dressing, eating, hygiene, etc.) or instrumental
(e.g. laundry, meal preparation, shopping, etc.) activities
and, a low-severity group, if no such assistance was
needed.
Costing methodology
A prevalence-based cost-of-illness approach was adopted
in order to estimate the utilisation of resources and cal-
culate costs from a societal perspective: direct health
care resources, non-health care resources (formal or in-
formal care), and productivity losses (i.e. indirect costs)
were measured. Specifically, a bottom-up costing ap-
proach was adopted based on which average annual
costs were estimated.
Resource use data were collected for all patients and,
if appropriate, for caregivers as well. Our survey tool re-
quested information for the period of 6 months preced-
ing the start of the study (or 12 months for the case of
hospital admissions), which were extrapolated to one
year. For the calculation of productivity losses patients
and caregivers provided information on working time re-
ductions they experienced (sick leave or/and early retire-
ment), with non-professional caregivers giving details on
any informal care they provided.
Health care utilisation assisted in the calculation of
direct medical costs by using unit costs and the respect-
ive mean patient utilisation to derive the cost of re-
sources used. All information concerning resource
utilisation data was obtained from the survey tool, in-
cluding hospital admissions and emergency visits num-
bers together with related outpatient care volume (e.g.
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medical examinations and tests, health care profes-
sionals’ visits, home care and rehabilitation).
The UK payment by results database was used to col-
lect data on unit costs [17], while other resources (pub-
licly accessible) were used to complete gaps in the data
[18, 19]. Annual costs per patient were derived by multi-
plying unit costs with the corresponding resource
amounts for the year 2012. Likewise, resource consump-
tion data concerning the utilisation of prescription drugs
and medical devices were also collected through the sur-
veys. For prescription drugs, in the case that units per
pack information was unavailable, the largest dispensa-
tion package was assumed; the unit costs of drugs were
collected from the National Drug Tariff database [20]
and the British National Formulary [21], while medical
devices unit costs were collected through online retails.
Direct non-health care costs were derived following
the aggregation of the following cost types: non-health
care transportation, social care services (i.e. formal care)
and caregiver’s time (i.e. informal care1). As part of in-
formal care, time spent helping patients with their basic
activities of daily living (ADL) and necessary instrumen-
tal activities of daily living were also considered. The
proxy good method was used to monetise the value of
caring hours by applying a professional caregiving hourly
rate to the informal caregiver’s time [22].
The social services category included evidence on for-
mal (i.e. paid) care supplied by professional caregivers,
along with other social services.
Productivity losses were derived by converting days of
work absence (due to sick leave or early retirement)
into economic cost by adopting a human capital ap-
proach [23], applying average national earnings data
from 2012 [24].
Patient & caregiver HRQoL
The EuroQol five dimensions (EQ-5D) instrument [25],
the Barthel Index [26] and the Zarit Burden Interview
[27] were used to collect patient and caregiver outcomes.
The EQ-5D tool is a generic HRQoL instrument regu-
larly used as part of health technology assessment
(HTA). It consists of two components, the EQ-5D de-
scriptive system which produces index scores from 0 to
1 (corresponding to the states of death and perfect
health respectively) consisting of five dimensions (mobil-
ity, self-care, everyday activities, pain/discomfort and
anxiety/depression), and the EQ-5D Visual Analogue
Scale (VAS), comprised from a vertical 20-cm scale and
ranging from 0 to 100 (denoting the worst and best im-
aginable health states respectively) [25]. For the UK gen-
eral public, valuations for different health states have
been modelled [28].
The Barthel Index is a measure of physical disability
being extensively used to assess a person’s ability to
complete ten basic ADLs, producing a numerical meas-
ure that reflects amount of dependence. For the UK,
overall scores fluctuate between 0 and 20, with higher
scores denoting lower disability, and therefore depend-
ence, and vice versa [26].
The Zarit Burden Interview is a self-reported measure
used to express burden among caregivers. Items on this
instrument correspond to statements that caregivers re-
spond to through a 5-point scale that ranges between 0
and 4, denoting never and nearly always respectively.
Overall scores produced can fluctuate from 0 to 88, with
>61 reflecting severe burden and scores <21 representing
little or no burden to caregivers [27].
Results
In total, 38 questionnaires were received from JIA pa-
tients out of the 62 questionnaires sent. Among these,
15 questionnaires were excluded because of insufficient
or inadequate information, producing a valid sample of
23 patient questionnaires in total.
Patients’ characteristics are summarised in Table 1.
There were ten adult patients and 13 adolescent patients
with their average age being 21 years (average age of
diagnosis was 5 years); 21.7 % of patients were males
and 43.5 % of patients were supported by a caregiver
with an average age of 43.1 years. The sample comprised
the following disease sub-types: systemic-onset juvenile
arthritis (Still’s disease) 30.4 % (n = 7), oligoarticular
arthritis 26.1 % (n = 6), rheumatoid factor-positive poly-
arthritis 17.4 % (n = 4), rheumatoid factor-negative poly-
arthritis 8.7 % (n = 2), enthesitis-related arthritis
(spondylarthropathies) 4.3 % (n = 1), juvenile psoriatic
arthritis 4.3 % (n = 1), unclassified types 8.7 % (n = 2).
The average total time spent on informal caregiving, de-
noting the existence of minimum one dedicated care-
giver, was 20.8 h each week, (or 1,087 h per year).
In 2012, the average cost per patient was calculated at
€31,546 (Table 2), about half of which was attributed to
direct health care (HC) costs (46.0 %), and the other half
being evenly divided between productivity losses (PL)
(27.6 %) and direct non-health care (NH) costs (26.7 %)
(Fig. 1). The largest HC cost category was prescription
medications averaging €6,667 (46.0 % of HC costs,
21.1 % of overall costs) followed by outpatient and pri-
mary health care visits (28.7 % of HC costs, 13.2 % of
overall costs) and diagnostic tests (17.2 % of HC costs,
7.9 % of overall costs) (Fig. 2). Informal care constituted
the highest NH costs, with €7,601 on average (91.3 % of
NH costs, 24.1 % of overall costs), largely relating to
main caregiver costs (68.0 % of NH costs, 17.9 % of
overall costs). Professional carer costs comprised 7.2 %
of NH costs and 1.9 % of overall costs, whereas non-
health care transport amounted to 0.9 % of NH costs
and 0.2 % of overall costs. Social services represented
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0.6 % of NH costs and 0.2 % of overall costs. Finally, early
retirement amounted to €8,526 accounting for 97.8 % of
PL and 27.0 % of overall costs, whereas sick leave
accounted for just 2.2 % of PL and 0.6 % of overall costs.
Whether or not a JIA patient needed caregiver assist-
ance, impacted greatly the results. A JIA patient with
caregiver assistance accumulated an average overall cost
of €39,469 per year, compared with €25,452 for a patient
where caregiver assistance was not needed. In the pres-
ence of a caregiver, informal care was the greatest cost
attribute, averaging €17,481 (44.3 % of overall costs).
Direct HC and NH costs respectively represented 26.8 %
and 48.0 % of overall costs. With regards to HC cost
types, outpatient and primary health care ranked at top
(44.9 % of HC costs, 12.0 % of overall costs), followed by
medications (33.0 % of HC costs, 8.9 % of overall costs),
and diagnostic tests (15.9 % of HC costs, 4.3 % of overall
costs). Professional care amounted to 7.2 % of NH costs
and 3.5 % of overall costs. A loss in productivity
amounted to 25.2 % of overall costs, with early retire-
ment accounting for 98.7 % of PL and 24.8 % of overall
costs respectively.
Where a carer was not required, HC and NH costs
amounted to 68.9 % and 0.6 % of overall costs respect-
ively, with PL amounting to 30.6 % of overall costs. The
greatest attributes of HC costs were medications (52 %
of HC costs, 35.8 % of overall costs), outpatient visits
(21.2 % of HC costs, 14.6 % of overall costs) and diag-
nostic tests (17.8 % of HC costs and 12.3 % of overall
costs). Only 0.4 % and 0.2 % of overall costs were attrib-
uted to social health services and non-health care trans-
port respectively. Finally, sick leave and early retirement
attributed 3.1 % and 96.9 % of PL and 0.9 % and 29.6 %
of overall costs respectively.
In terms of adult patients’ HRQoL, the mean EQ-5D
index score was estimated to be 0.26 and the mean EQ-
5D VAS score was 49 (out of 1.00 and 100 respectively)
(Table 1). Both scores were below the respective age-
adjusted values of the UK public (0.91 and 86.56 respect-
ively) [29]. Similarly, the mean EQ-5D index and VAS
scores for carers were 0.66 and 67.14 respectively
(Table 1), both being considerably lower than the age-
adjusted UK public values. The average Barthel index
among adult patients was 16.2 associated with moderate
dependence, whereas the average Zarit interview burden
score was 22.9, suggesting a mild to moderate burden
for those in care of patients (Table 1).
Discussion
The above findings suggest that JIA is likely having a con-
siderable economic impact on the UK, especially with
regards to non-health care costs representing more than
half of overall average costs, and with the HRQoL of JIA
patients being substantially below public valuations.
Among the low prevalence diseases and orphan indi-
cations space, JIA represents a clinical condition with
important societal impact and significant cost burden
in high-income countries, including in the UK. Its
Table 1 Sample characteristics of JIA patient sample (n = 23, SD
in brackets)
Average age (years)
All patients (n = 23) 21.4 (16.8)
Adult patients (n = 10) 38.5 (9.8)
Adolescent patients (n = 13) 8.3 (3.8)
Average diagnosis age (years)
All patients (n = 23) 5.2 (4.4)
Adult patients (n = 10) 5.9 (5.2)
Adolescent patients (n = 13) 4.6 (3.9)
Sex
Male 21.7 %
Female 78.3 %
Disease subtype
Systemic-onset juvenile arthritis (Still’s disease) 30.4 %
Oligoarticular arthritis 26.1 %
Rheumatoid factor-positive polyarthritis 17.4 %
Rheumatoid factor-negative polyarthritis 8.7 %
Enthesitis-related arthritis (spondylarthropathies) 4.3 %
Juvenile psoriatic arthritis 4.3 %
Unclassified types 8.7 %
Is there a caregiver?
Yes (n = 10) 43.5 %
No (n = 13) 56.5 %
Average age of (principal) caregiver (years) 43.1 (9.7)
Average informal care hours per week (whole sample) 11.8 (29.1)
Average informal care hours per week
(if there is a caregiver)
20.3 (23.6)
Health Related Quality of Life (Visual Analog Scale)
Adult JIA patients (n = 10) 49.00 (12.43)
Visual Analog Scale score for general populationa 86.56 (13.79)
Main Caregivers for JIA patients (n = 7) 67.14 (26.12)
Visual Analog Scale score for general populationb 86.56 (13.79)
Health Related Quality of Life (EQ-5D index score)
Adult JIA patients (n = 10) 0.262 (0.239)
EQ-5D index score for general populationa 0.91 (0.16)
Main Caregivers for JIA patients (n = 7) 0.663 (0.367)
EQ-5D index score for general populationb 0.91 (0.16)
Average Barthel Index (n = 17) 16.2 (3.6)
Average Zarit scale (n = 8) 22.9 (6.6)
aReflects general population social tariffs/utilities for the respective patients’
age group (i.e. 35–44)
bReflects general population social tariffs/utilities for the respective caregivers’
age group (i.e. 35–44)
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prevalence, incidence, mortality and morbidity com-
bined with a high socioeconomic impact, i.e. cost and
HRQoL, requires attention from health authorities.
There is a lack of socioeconomic research into the
burden of JIA. A recent systematic literature review in-
dicated nine available studies on JIA costs [30]. JIA’s
economic impact was investigated in seven of the
studies [2, 13, 14, 31–34], one study looked into eta-
nercept’s (TNF-alpha inhibitor) impact on overall costs
[35], and another investigated JIA hydrotherapy’s cost-
effectiveness [36]. Some of the studies also highlighted the
significant costs associated with JIA while at the same
time showing substantial variation between subgroups.
Measured in 2012 €, average overall cost per year was
Table 2 Average annual costs per JIA patient (2012, in €)
Total (n = 23) Without Carer (n = 13) With Carer (n = 10)
Mean SD Mean SD Mean SD
Health Care Costs
Medication 6,667 9,206 9,105 11,060 3,496 4,931
Tests 2,493 2,662 3,114 3,335 1,686 1,101
Outpatient and primary health care visits 4,169 3,206 3,718 3,355 4,754 3,074
Acute hospitalisation 1,047 2,962 1,451 3,894 522 826
Devices 114 162 100 131 132 201
Health care transportation 19 92 33 120 0 0
Subtotal 14,508 14,877 17,523 18,331 10,590 7,926
Non-Health Care Costs
Social services 50 241 89 320 0 0
Professional carer 597 2,546 0 0 1,372 3,830
Non-health care transportation 75 143 59 146 96 145
Caregiver time costs (informal care) 7,601 18,703 0 0 17,481 25,751
Main caregivers 5,661 11,722 0 0 13,020 15,147
Secondary caregivers 1,940 9,027 0 0 4,462 13,663
Subtotal 8,323 18,665 148 338 18,950 25,089
Total Direct Costs (Health Care Costs & Non-Health Care Costs) 22,831 24,728 17,671 18,550 29,540 30,862
Productivity Loss
Sick leave 190 513 240 600 125 395
Early retirement 8,525 14,673 7,542 14,332 9,804 15,786
Subtotal 8,715 14,566 7,782 14,636 9,929 15,705
TOTAL COSTS 31,546 28,568 25,452 27,146 39,469 29,817
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
Health Care Costs
Non-Health Care Costs
Productivity Loss
All patients Without carer With carer
Fig. 1 Average breakdown of costs across different patient study groups (2012, €)
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calculated at €4,143 (€3,471 in 1999) [2] and €29,613 (US
$33,171 in 2000) [35] per patient, indicating that 80 % of
total costs may be caused by only a fraction of patients,
and over 50 % of direct costs may stem from the treat-
ment of only a small proportion of inpatient cases [2].
Loss of parents’ income has been used by Minden and col-
leagues to reflect indirect costs in Germany, initially esti-
mated annually for each patient at €1,870 or 86 % of direct
costs in 1999, subsequently declining respectively to €274
or 6 % of direct costs annually in 2008 [34], possibly due to
the introduction of more effective drug therapies (TNFα
inhibitors) enabling caregiving parents to return to work.
Indeed, a Finnish study showed a reduction of 50 % in in-
direct costs at €1,507 following the introduction of TNFα
inhibitors, associated with an additional €3,767 direct costs
per patient annually [35], and another study in the UK set-
ting estimated indirect costs much lower at €142 per pa-
tient per year (5 % of direct costs) [36]. In respect to direct
costs, these have been estimated at €4,464 (€4,403 in 2008)
[34] with other estimates for direct healthcare costs ran-
ging from €2,202 (GBP 1,649 in 2005) [13] to €9,273 (US
$7,904 in 1992) [31], and the greatest attribute being eta-
nercept treatment at €27,603 (US $30,919 in 2000) ac-
counting for up to 54 % of direct costs [35]. Depending on
the study, direct costs accounted between 6 % and 55 % of
total costs, with health care costs comprising 95 % of direct
costs, and 60 % of health care costs accredited to out-
patient visits with the remaining 40 % to inpatient [2, 34].
Low expenditure on medical devices compared to early
2000s might be partly attributed to changing patterns of
care, as reflected through the shift from application of arti-
ficial joints (AJs) in adult patients, which is now a rare
event, to treatment with DMARDs, including MTX and
TNF-alpha inhibitors. Overall, costs were shown to be
skewed towards active patients with mean total costs being
over seven times higher for patients in remission [2], and
with a substantial sub-group variation.
Of all studies, only two addressed the UK context
[13, 36] and only one measured productivity losses by
using parents’ time away from work [36].
This study represents the first UK attempt to quantify
the total cost for JIA patients while measuring direct
non-healthcare costs. The present research draws atten-
tion to the significance of examining the monetary im-
pact of JIA from a societal standpoint and the need for a
cross-country understanding. The study’s results provide
us with knowledge on how JIA costs are distributed and
also the strain such costs add to the healthcare system,
together with the impact on patient and caregivers ex-
penses. The overall average cost of €31,546 per year
(€25,452 to €39,468 respectively for patients without
and with caregivers), is associated with significant ex-
penditures related to early retirement (27.0 % of overall
cost), informal care (24.1 %), medications (21.1 %), out-
patient and primary health care visits (13.2 %) and diag-
nostic tests (7.9 %).
The relatively greater impact of informal care and in-
direct costs in our results compared with earlier studies
may have several explanations, which, ultimately, can
be attributed to the methodology adopted. For example,
although earlier cost-of-illness studies have generally
incorporated employment loss and informal care as
part of indirect costs, later studies adopt overwhelm-
ingly more detailed societal cost categories. In our
study we have observed high (informal) care and high
early retirement costs, the latter possibly due to the
relatively young age of the patient population
(38.5 years). Other studies on JIA have proxied indirect
costs through productivity losses of the caregiver [34,
36]. Our results are likely underestimating real JIA
costs due to the exclusion of institutionalised patients
and any long-term care costs. Finally, by quantifying
costs attributed to informal caregiving, our study shows
informal care to be a major cost to UK society, which
0
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Fig. 2 Average costs per JIA patient broken down by type of cost (2012, €)
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could be regarded as ‘hidden’ cost given the absence of
acknowledgement in other studies.
For priority-setting and evaluation of health care inter-
ventions, HRQoL has been found to be a valuable measure
in combination with other epidemiological, clinical and
economic evidence on incidence, prevalence, mortality
and costs. Our results illustrate that mean EQ-5D index
scores both for adult JIA patients (0.26) and caregivers
(0.66) are substantially lower than the (age-adjusted)
equivalent in the general population (0.91), indicating
lower quality of life. Despite its low prevalence, JIA results
in a considerable monetary burden, with higher depend-
ency patients being associated with greater productivity
losses than lower dependency patients.
Our study has a number of drawbacks, as for example
issues relating to sampling. The adopted recruitment
process and study sample may reduce results’ external
validity; although there were almost even proportions of
high- and low-severity patients in our sample, selection
bias is frequent among studies of rare diseases where
few patient numbers is the general norm. Second, given
that patient reported information was collected via a
survey tool there might be potential recall bias and a 6-
month recall period would not exclude this possibility. A
third limit results from the exclusion of any JIA-specific
HRQoL tools, such as the Juvenile Arthritis Quality of
Life Questionnaire [37–39] or Arthritis Impact Measure-
ment Scales [40]. Nevertheless, recently a systematic lit-
erature review on the use of various HRQoL instruments
in the space of rare diseases suggested that the EQ-5D
could be regarded as a valid measure for generic health
outcomes in JIA disease progression [41]. Lastly, we
employed cross-sectional data; ideally we should have
adopted a prospective longitudinal study design, however
this was not possible and to our best knowledge no such
analysis has yet been carried out to study JIA.
Regardless of its limits, we believe our work is the
most comprehensive and representative costing exercise
on the burden of JIA in the UK to date, with the main
advantage centring on the adoption of a bottom-up cost-
ing approach over a one-year period.
Conclusion
This bottom-up aggregate cost and HRQoL study sug-
gests that in the UK there are substantial health care
costs due to JIA, nonetheless other societal costs, such
as early retirement and informal caregiving, are propor-
tionately greater, with disability being associated with
significantly higher JIA societal costs. Overall, JIA pre-
sents an important societal cost being linked to a sub-
stantial HRQoL deterioration. These findings could be
considered when examining treatment options for JIA
sufferers and support program options for patients and
caregivers alike. The study results could support the
formation of integrated approaches for the periodic
evaluation of rare diseases’ novel treatments and public
policies impact, both within the UK and at a broader
supranational level.
Endnotes
1Such care is provided by non-professional caregivers
who are not remunerated, primarily being relatives,
friends or neighbours of patients.
Appendix: BURQOL-RD research network
 Canary Islands Foundation for Research and Health
(FUNCIS) (Spain): Pedro Serrano-Aguilar, Renata
Linertová
 Universidad Castilla-La Mancha (Spain): Julio
López-Bastida, Juan Oliva-Moreno
 Research Institute for Rare Diseases, Instituto de
Salud Carlos III (Spain): Manuel Posada de la Paz,
Manuel Hens Pérez, Ignacio Abaitua
 National Center for Rare Diseases, Istituto
Superiore di Sanità (Italy): Domenica Taruscio,
Yllka Kodra
 Mario Negri Institute for Pharmacological Research
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